Analyst Research

Report Title Price
Provider: Ford Investor Services, Inc.
$12.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Capricor Therapeutics announces encouraging results from Phase I ALLSTAR Trial; Phase II trial underway


Wednesday, 16 Jul 2014 07:59am EDT 

Capricor Therapeutics Inc:Says encouraging analysis of completion of its MRI data at the six-month time point from Capricor's Phase I ALLSTAR trial.Study revealed that those patients who would be included in the Phase II clinical study, by virtue of dose and tissue type compatibility, exhibited measurable improvements in ejection fraction, a global measure of the heart's pumping ability.Starts enrolling ALLSTAR Phase II, a clinical trial evaluating the effectiveness of CAP-1002 in reducing infarct size in patients who have suffered a myocardial infarction (heart attack) more than 30 days and less than 12 months prior to treatment with CAP-1002. 

Company Quote

3.5001
-0.2599 -6.91%
30 Oct 2014